You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFenfluramine
Accession NumberDB00574  (APRD00319)
TypeSmall Molecule
GroupsIllicit, Withdrawn
DescriptionFenfluramine was withdrawn from the U.S. market in 1997 after reports of heart valve disease and pulmonary hypertension, including a condition known as cardiac fibrosis.
Structure
Thumb
Synonyms
Fenfluramina
Fenfluraminum
External Identifiers
  • DEA No. 1670
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Pondimin Tab 20mgtablet20 mgoralAyerst Laboratories1991-12-311997-08-15Canada
Pondimin Tab 20mgtablet20 mgoralWyeth Ayerst Canada Inc.1996-09-231998-08-13Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AdifaxNot Available
PonderaxNot Available
PondiminNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Fenfluramine hydrochloride
Thumb
  • InChI Key: ZXKXJHAOUFHNAS-UHFFFAOYNA-N
  • Monoisotopic Mass: 267.100161871
  • Average Mass: 267.718
DBSALT000802
Categories
UNII2DS058H2CF
CAS number458-24-2
WeightAverage: 231.2573
Monoisotopic: 231.123484132
Chemical FormulaC12H16F3N
InChI KeyInChIKey=DBGIVFWFUFKIQN-UHFFFAOYSA-N
InChI
InChI=1S/C12H16F3N/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15/h4-6,8-9,16H,3,7H2,1-2H3
IUPAC Name
ethyl({1-[3-(trifluoromethyl)phenyl]propan-2-yl})amine
SMILES
CCNC(C)CC1=CC(=CC=C1)C(F)(F)F
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenethylamines
Direct ParentAmphetamines and derivatives
Alternative Parents
Substituents
  • Amphetamine or derivatives
  • Phenylpropane
  • Aralkylamine
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the management of exogenous obesity as a short-term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction.
PharmacodynamicsUsed to treat obesity, Fenfluramine decreases caloric intake by increasing serotonin levels in the brain's synapses. Fenfluramine acts as a serotonin reuptake inhibitor. It also causes release of serotonin from the synaptosomes. This in turn increases serotonin transmission in the feeding centre of the brain which suppresses appetite.
Mechanism of actionFenfluramine binds to the serotonin reuptake pump. This causes inhbition of serotonin uptake and release of serotonin. The increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates.
Related Articles
AbsorptionFenfluramine is well-absorbed from the gastrointestinal tract, and a maximal anorectic effect is generally seen after 2 to 4 hours.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

SubstrateEnzymesProduct
Fenfluramine
norfenfluramineDetails
Route of eliminationNot Available
Half life20 hours
ClearanceNot Available
ToxicityAgitation and drowsiness, confusion, flushing, tremor (or shivering), fever, sweating, abdominal pain, hyperventilation, and dilated non-reactive pupils seem frequent in fenfluramine overdosage. Reflexes may be either exaggerated or depressed and some patients may have rotary nystagmus. Tachycardia may be present, but blood pressure may be normal or only slightly elevated. Convulsions, coma, and ventricular extrasystoles, culminating in ventricular fibrillation, and cardiac arrest, may occur at higher dosages. Less than 5 mg/kg are toxic to humans. Five-ten mg/kg may produce coma and convulsions. Reported single overdoses have ranged from 300 to 2000 mg; the lowest reported fatal dose was a few hundred mg in a small child, and the highest reported nonfatal dose was 1800 mg in an adult. Most deaths were apparently due to respiratory failure and cardiac arrest. Toxic effects will appear within 30 to 60 minutes and may progress rapidly to potentially fatal complications in 90 to 240 minutes. Symptoms may persist for extended periods depending upon the dose ingested.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9868
Caco-2 permeable+0.7004
P-glycoprotein substrateNon-substrate0.5138
P-glycoprotein inhibitor INon-inhibitor0.5934
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.7404
CYP450 2C9 substrateNon-substrate0.8506
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.6781
CYP450 1A2 substrateInhibitor0.8859
CYP450 2C9 inhibitorNon-inhibitor0.8616
CYP450 2D6 inhibitorInhibitor0.7253
CYP450 2C19 inhibitorNon-inhibitor0.5205
CYP450 3A4 inhibitorNon-inhibitor0.5219
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6657
Ames testNon AMES toxic0.8808
CarcinogenicityNon-carcinogens0.6397
BiodegradationNot ready biodegradable0.984
Rat acute toxicity3.1255 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9666
hERG inhibition (predictor II)Inhibitor0.7811
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral20 mg
PricesNot Available
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point108-112 °C at 1.20E+01 mm HgNot Available
water solubility412 mg/LNot Available
logP3.36SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.0215 mg/mLALOGPS
logP3.3ALOGPS
logP3.47ChemAxon
logS-4ALOGPS
pKa (Strongest Basic)10.22ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity59.2 m3·mol-1ChemAxon
Polarizability22.51 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Vincenzo Cannata, Barbara Galbiati, Angelo Spreafico, “Process for manufacturing 1-(3-trifluoromethyl)-phenyl-propan-2-one intermediate in the synthesis of the fenfluramine.” U.S. Patent US5811586, issued August, 1965.

US5811586
General References
  1. Roth BL: Drugs and valvular heart disease. N Engl J Med. 2007 Jan 4;356(1):6-9. [PubMed:17202450 ]
External Links
ATC CodesA08AA02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (47.2 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Fenfluramine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Fenfluramine.
AcarboseFenfluramine may increase the hypoglycemic activities of Acarbose.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Fenfluramine.
AcenocoumarolFenfluramine may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Fenfluramine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Fenfluramine.
Acetylsalicylic acidFenfluramine may increase the antiplatelet activities of Acetylsalicylic acid.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Fenfluramine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Fenfluramine.
AlbiglutideFenfluramine may increase the hypoglycemic activities of Albiglutide.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Fenfluramine.
AlfentanilAlfentanil may increase the serotonergic activities of Fenfluramine.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Fenfluramine.
AlogliptinFenfluramine may increase the hypoglycemic activities of Alogliptin.
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Fenfluramine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fenfluramine.
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Fenfluramine.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Fenfluramine.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fenfluramine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fenfluramine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Fenfluramine.
AmoxapineFenfluramine may increase the serotonergic activities of Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Fenfluramine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fenfluramine.
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Fenfluramine.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Fenfluramine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Fenfluramine.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Fenfluramine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Fenfluramine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Fenfluramine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Fenfluramine.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Fenfluramine.
BefunololThe serum concentration of Befunolol can be increased when it is combined with Fenfluramine.
BendroflumethiazideFenfluramine may increase the hyponatremic activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the serotonergic activities of Fenfluramine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Fenfluramine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Fenfluramine.
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Fenfluramine.
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Fenfluramine.
BezitramideBezitramide may increase the serotonergic activities of Fenfluramine.
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Fenfluramine.
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Fenfluramine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Fenfluramine.
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Fenfluramine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fenfluramine.
BromocriptineFenfluramine may increase the hypoglycemic activities of Bromocriptine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Fenfluramine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Fenfluramine.
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Fenfluramine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fenfluramine.
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Fenfluramine.
BuprenorphineBuprenorphine may increase the serotonergic activities of Fenfluramine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Fenfluramine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fenfluramine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Fenfluramine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Fenfluramine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Fenfluramine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Fenfluramine.
ButorphanolButorphanol may increase the serotonergic activities of Fenfluramine.
CanagliflozinFenfluramine may increase the hypoglycemic activities of Canagliflozin.
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Fenfluramine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fenfluramine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Fenfluramine.
CarfentanilCarfentanil may increase the serotonergic activities of Fenfluramine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Fenfluramine.
CaroxazoneCaroxazone may increase the serotonergic activities of Fenfluramine.
CarteololThe serum concentration of Carteolol can be increased when it is combined with Fenfluramine.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Fenfluramine.
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Fenfluramine.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Fenfluramine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fenfluramine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fenfluramine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Fenfluramine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fenfluramine.
ChlorothiazideFenfluramine may increase the hyponatremic activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fenfluramine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fenfluramine.
ChlorpropamideFenfluramine may increase the hypoglycemic activities of Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fenfluramine.
ChlorthalidoneFenfluramine may increase the hyponatremic activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Fenfluramine.
CimetidineThe metabolism of Fenfluramine can be decreased when combined with Cimetidine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fenfluramine.
CitalopramCitalopram may increase the serotonergic activities of Fenfluramine.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Fenfluramine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Fenfluramine.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Fenfluramine.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Fenfluramine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Fenfluramine.
ClomipramineFenfluramine may increase the serotonergic activities of Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Fenfluramine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Fenfluramine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fenfluramine.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Fenfluramine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Fenfluramine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Fenfluramine.
CodeineCodeine may increase the serotonergic activities of Fenfluramine.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Fenfluramine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fenfluramine.
CyproheptadineThe therapeutic efficacy of Fenfluramine can be decreased when used in combination with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Fenfluramine.
DapagliflozinFenfluramine may increase the hypoglycemic activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fenfluramine.
DapoxetineFenfluramine may increase the serotonergic activities of Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Fenfluramine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Fenfluramine.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Fenfluramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Fenfluramine.
DesmopressinThe risk or severity of adverse effects can be increased when Fenfluramine is combined with Desmopressin.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Fenfluramine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fenfluramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fenfluramine.
DextromethorphanFenfluramine may increase the serotonergic activities of Dextromethorphan.
DextromoramideDextromoramide may increase the serotonergic activities of Fenfluramine.
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Fenfluramine.
DezocineDezocine may increase the serotonergic activities of Fenfluramine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Fenfluramine.
DicoumarolFenfluramine may increase the anticoagulant activities of Dicoumarol.
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Fenfluramine.
DihydrocodeineDihydrocodeine may increase the serotonergic activities of Fenfluramine.
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Fenfluramine.
DihydromorphineDihydromorphine may increase the serotonergic activities of Fenfluramine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Fenfluramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fenfluramine.
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Fenfluramine.
DisopyramideFenfluramine may increase the hypoglycemic activities of Disopyramide.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Fenfluramine.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Fenfluramine.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Fenfluramine.
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Fenfluramine.
DPDPEDPDPE may increase the serotonergic activities of Fenfluramine.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Fenfluramine.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Fenfluramine.
DulaglutideFenfluramine may increase the hypoglycemic activities of Dulaglutide.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fenfluramine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Fenfluramine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Fenfluramine.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Fenfluramine.
EmpagliflozinFenfluramine may increase the hypoglycemic activities of Empagliflozin.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Fenfluramine.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Fenfluramine.
EscitalopramFenfluramine may increase the serotonergic activities of Escitalopram.
EsmololThe serum concentration of Esmolol can be increased when it is combined with Fenfluramine.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Fenfluramine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fenfluramine.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Fenfluramine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fenfluramine.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fenfluramine.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Fenfluramine.
Ethyl biscoumacetateFenfluramine may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fenfluramine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Fenfluramine.
EthylmorphineEthylmorphine may increase the serotonergic activities of Fenfluramine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Fenfluramine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Fenfluramine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Fenfluramine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Fenfluramine.
EtoperidoneFenfluramine may increase the serotonergic activities of Etoperidone.
EtorphineEtorphine may increase the serotonergic activities of Fenfluramine.
ExenatideFenfluramine may increase the hypoglycemic activities of Exenatide.
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Fenfluramine.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Fenfluramine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fenfluramine.
FentanylFentanyl may increase the serotonergic activities of Fenfluramine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fenfluramine.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Fenfluramine.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Fenfluramine.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Fenfluramine.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Fenfluramine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Fenfluramine.
FluoxetineFluoxetine may increase the serotonergic activities of Fenfluramine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fenfluramine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fenfluramine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fenfluramine.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Fenfluramine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Fenfluramine.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Fenfluramine.
FluvoxamineFenfluramine may increase the serotonergic activities of Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Fenfluramine.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Fenfluramine.
FurazolidoneFurazolidone may increase the serotonergic activities of Fenfluramine.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fenfluramine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Fenfluramine.
GalantamineThe metabolism of Galantamine can be decreased when combined with Fenfluramine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Fenfluramine.
GliclazideFenfluramine may increase the hypoglycemic activities of Gliclazide.
GlimepirideFenfluramine may increase the hypoglycemic activities of Glimepiride.
GlipizideFenfluramine may increase the hypoglycemic activities of Glipizide.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Fenfluramine.
GlyburideFenfluramine may increase the hypoglycemic activities of Glyburide.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Fenfluramine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Fenfluramine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fenfluramine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Fenfluramine.
HeroinHeroin may increase the serotonergic activities of Fenfluramine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fenfluramine.
HydracarbazineHydracarbazine may increase the serotonergic activities of Fenfluramine.
HydrochlorothiazideFenfluramine may increase the hyponatremic activities of Hydrochlorothiazide.
HydrocodoneHydrocodone may increase the serotonergic activities of Fenfluramine.
HydroflumethiazideFenfluramine may increase the hyponatremic activities of Hydroflumethiazide.
HydromorphoneHydromorphone may increase the serotonergic activities of Fenfluramine.
HydroxyzineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Fenfluramine.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Fenfluramine.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Fenfluramine.
IndalpineFenfluramine may increase the serotonergic activities of Indalpine.
IndapamideFenfluramine may increase the hyponatremic activities of Indapamide.
IndenololThe serum concentration of Indenolol can be increased when it is combined with Fenfluramine.
Insulin AspartFenfluramine may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirFenfluramine may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineFenfluramine may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineFenfluramine may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanFenfluramine may increase the hypoglycemic activities of Insulin Human.
Insulin LisproFenfluramine may increase the hypoglycemic activities of Insulin Lispro.
Ioflupane I-123Fenfluramine may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
IproclozideIproclozide may increase the serotonergic activities of Fenfluramine.
IproniazidIproniazid may increase the serotonergic activities of Fenfluramine.
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Fenfluramine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Fenfluramine.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Fenfluramine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Fenfluramine.
KetobemidoneKetobemidone may increase the serotonergic activities of Fenfluramine.
L-TryptophanL-Tryptophan may increase the serotonergic activities of Fenfluramine.
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Fenfluramine.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fenfluramine.
LanreotideFenfluramine may increase the hypoglycemic activities of Lanreotide.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Fenfluramine.
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Fenfluramine.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Fenfluramine.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Fenfluramine.
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Fenfluramine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Fenfluramine.
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Fenfluramine.
LevomilnacipranFenfluramine may increase the serotonergic activities of Levomilnacipran.
LevorphanolLevorphanol may increase the serotonergic activities of Fenfluramine.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Fenfluramine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Fenfluramine.
LinezolidLinezolid may increase the serotonergic activities of Fenfluramine.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Fenfluramine.
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Fenfluramine.
LiraglutideFenfluramine may increase the hypoglycemic activities of Liraglutide.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Fenfluramine.
LofentanilLofentanil may increase the serotonergic activities of Fenfluramine.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Fenfluramine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fenfluramine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fenfluramine.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Fenfluramine.
Lu AA21004Fenfluramine may increase the serotonergic activities of Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Fenfluramine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Fenfluramine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Fenfluramine.
MebanazineMebanazine may increase the serotonergic activities of Fenfluramine.
MecaserminFenfluramine may increase the hypoglycemic activities of Mecasermin.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Fenfluramine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Fenfluramine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Fenfluramine.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Fenfluramine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fenfluramine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fenfluramine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fenfluramine.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fenfluramine.
MetforminFenfluramine may increase the hypoglycemic activities of Metformin.
MethadoneThe metabolism of Methadone can be decreased when combined with Fenfluramine.
MethadoneMethadone may increase the serotonergic activities of Fenfluramine.
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Fenfluramine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Fenfluramine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Fenfluramine.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fenfluramine.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Fenfluramine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Fenfluramine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fenfluramine.
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Fenfluramine.
MethyclothiazideFenfluramine may increase the hyponatremic activities of Methyclothiazide.
Methylene blueFenfluramine may increase the serotonergic activities of Methylene blue.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fenfluramine.
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Fenfluramine.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fenfluramine.
MetolazoneFenfluramine may increase the hyponatremic activities of Metolazone.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Fenfluramine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Fenfluramine.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Fenfluramine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Fenfluramine.
MifepristoneFenfluramine may increase the hypoglycemic activities of Mifepristone.
MiglitolFenfluramine may increase the hypoglycemic activities of Miglitol.
MilnacipranFenfluramine may increase the serotonergic activities of Milnacipran.
MinaprineMinaprine may increase the serotonergic activities of Fenfluramine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Fenfluramine.
MoclobemideMoclobemide may increase the serotonergic activities of Fenfluramine.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Fenfluramine.
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Fenfluramine.
MorphineMorphine may increase the serotonergic activities of Fenfluramine.
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Fenfluramine.
NadololThe serum concentration of Nadolol can be increased when it is combined with Fenfluramine.
NalbuphineNalbuphine may increase the serotonergic activities of Fenfluramine.
NateglinideFenfluramine may increase the hypoglycemic activities of Nateglinide.
NialamideNialamide may increase the serotonergic activities of Fenfluramine.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Fenfluramine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Fenfluramine.
NormethadoneNormethadone may increase the serotonergic activities of Fenfluramine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fenfluramine.
OctamoxinOctamoxin may increase the serotonergic activities of Fenfluramine.
OctreotideFenfluramine may increase the hypoglycemic activities of Octreotide.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Fenfluramine.
OlanzapineFenfluramine may increase the serotonergic activities of Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fenfluramine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fenfluramine.
OpiumOpium may increase the serotonergic activities of Fenfluramine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Fenfluramine.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Fenfluramine.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fenfluramine.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Fenfluramine.
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Fenfluramine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fenfluramine.
OxycodoneOxycodone may increase the serotonergic activities of Fenfluramine.
OxymorphoneOxymorphone may increase the serotonergic activities of Fenfluramine.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fenfluramine.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Fenfluramine.
PargylinePargyline may increase the serotonergic activities of Fenfluramine.
ParoxetineFenfluramine may increase the serotonergic activities of Paroxetine.
PasireotideFenfluramine may increase the hypoglycemic activities of Pasireotide.
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Fenfluramine.
PentamidineFenfluramine may increase the hypoglycemic activities of Pentamidine.
PentazocinePentazocine may increase the serotonergic activities of Fenfluramine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fenfluramine.
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Fenfluramine.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Fenfluramine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fenfluramine.
PethidinePethidine may increase the serotonergic activities of Fenfluramine.
PhenelzinePhenelzine may increase the serotonergic activities of Fenfluramine.
PhenindioneFenfluramine may increase the anticoagulant activities of Phenindione.
PheniprazinePheniprazine may increase the serotonergic activities of Fenfluramine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fenfluramine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Fenfluramine.
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Fenfluramine.
PhenprocoumonFenfluramine may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Fenfluramine.
PimozideThe risk or severity of adverse effects can be increased when Fenfluramine is combined with Pimozide.
PindololThe serum concentration of Pindolol can be increased when it is combined with Fenfluramine.
PioglitazoneFenfluramine may increase the hypoglycemic activities of Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Fenfluramine.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Fenfluramine.
PirlindolePirlindole may increase the serotonergic activities of Fenfluramine.
PivhydrazinePivhydrazine may increase the serotonergic activities of Fenfluramine.
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Fenfluramine.
PolythiazideFenfluramine may increase the hyponatremic activities of Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Fenfluramine.
PractololThe serum concentration of Practolol can be increased when it is combined with Fenfluramine.
PramlintideFenfluramine may increase the hypoglycemic activities of Pramlintide.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Fenfluramine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Fenfluramine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fenfluramine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Fenfluramine.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Fenfluramine.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Fenfluramine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fenfluramine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Fenfluramine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Fenfluramine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fenfluramine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Fenfluramine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Fenfluramine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Fenfluramine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fenfluramine.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Fenfluramine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Fenfluramine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fenfluramine.
QuinethazoneFenfluramine may increase the hyponatremic activities of Quinethazone.
QuinineFenfluramine may increase the hypoglycemic activities of Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Fenfluramine.
RasagilineRasagiline may increase the serotonergic activities of Fenfluramine.
RemifentanilRemifentanil may increase the serotonergic activities of Fenfluramine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fenfluramine.
RepaglinideFenfluramine may increase the hypoglycemic activities of Repaglinide.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Fenfluramine.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Fenfluramine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Fenfluramine.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Fenfluramine.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fenfluramine.
RosiglitazoneFenfluramine may increase the hypoglycemic activities of Rosiglitazone.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Fenfluramine.
SafrazineSafrazine may increase the serotonergic activities of Fenfluramine.
SaxagliptinFenfluramine may increase the hypoglycemic activities of Saxagliptin.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fenfluramine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fenfluramine.
SelegilineSelegiline may increase the serotonergic activities of Fenfluramine.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Fenfluramine.
SertralineFenfluramine may increase the serotonergic activities of Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fenfluramine.
SitagliptinFenfluramine may increase the hypoglycemic activities of Sitagliptin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Fenfluramine.
SotalolThe serum concentration of Sotalol can be increased when it is combined with Fenfluramine.
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Fenfluramine.
SufentanilSufentanil may increase the serotonergic activities of Fenfluramine.
SulfadiazineFenfluramine may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleFenfluramine may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazoleFenfluramine may increase the hypoglycemic activities of Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fenfluramine.
SunitinibFenfluramine may increase the hypoglycemic activities of Sunitinib.
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Fenfluramine.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Fenfluramine.
TapentadolTapentadol may increase the serotonergic activities of Fenfluramine.
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Fenfluramine.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Fenfluramine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Fenfluramine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Fenfluramine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Fenfluramine.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Fenfluramine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fenfluramine.
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Fenfluramine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Fenfluramine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Fenfluramine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fenfluramine.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fenfluramine.
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Fenfluramine.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Fenfluramine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Fenfluramine.
TimololThe serum concentration of Timolol can be increased when it is combined with Fenfluramine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Fenfluramine.
TolazamideFenfluramine may increase the hypoglycemic activities of Tolazamide.
TolbutamideFenfluramine may increase the hypoglycemic activities of Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fenfluramine.
ToloxatoneToloxatone may increase the serotonergic activities of Fenfluramine.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Fenfluramine.
TramadolFenfluramine may increase the neuroexcitatory activities of Tramadol.
TramadolTramadol may increase the serotonergic activities of Fenfluramine.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Fenfluramine.
TranylcypromineTranylcypromine may increase the serotonergic activities of Fenfluramine.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Fenfluramine.
TrazodoneFenfluramine may increase the serotonergic activities of Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Fenfluramine.
TrichlormethiazideFenfluramine may increase the hyponatremic activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fenfluramine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fenfluramine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fenfluramine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Fenfluramine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Fenfluramine.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Fenfluramine.
VilazodoneFenfluramine may increase the serotonergic activities of Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Fenfluramine.
VortioxetineFenfluramine may increase the serotonergic activities of Vortioxetine.
WarfarinFenfluramine may increase the anticoagulant activities of Warfarin.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Fenfluramine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fenfluramine.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Fenfluramine.
ZimelidineFenfluramine may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Fenfluramine.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Fenfluramine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Fenfluramine.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Fenfluramine.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Fenfluramine.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Fenfluramine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fenfluramine.
Food Interactions
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Rothman RB, Zolkowska D, Baumann MH: Serotonin (5-HT) transporter ligands affect plasma 5-HT in rats. Ann N Y Acad Sci. 2008 Oct;1139:268-84. doi: 10.1196/annals.1432.042. [PubMed:18991872 ]
  2. Cosgrove KP, Staley JK, Baldwin RM, Bois F, Plisson C, Al-Tikriti MS, Seibyl JP, Goodman MM, Tamagnan GD: SPECT imaging with the serotonin transporter radiotracer [123I]p ZIENT in nonhuman primate brain. Nucl Med Biol. 2010 Jul;37(5):587-91. doi: 10.1016/j.nucmedbio.2010.03.007. Epub 2010 May 6. [PubMed:20610163 ]
  3. Xie T, Tong L, McLane MW, Hatzidimitriou G, Yuan J, McCann U, Ricaurte G: Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines. Neuropsychopharmacology. 2006 Dec;31(12):2639-51. Epub 2006 Jan 25. [PubMed:16452989 ]
  4. Johnson GJ, Leis LA, Dunlop PC, Weir EK: The effect of the anorectic agent, d-fenfluramine, and its primary metabolite, d-norfenfluramine, on intact human platelet serotonin uptake and efflux. J Thromb Haemost. 2003 Dec;1(12):2663-8. [PubMed:14675103 ]
  5. Rothman RB, Jayanthi S, Wang X, Dersch CM, Cadet JL, Prisinzano T, Rice KC, Baumann MH: High-dose fenfluramine administration decreases serotonin transporter binding, but not serotonin transporter protein levels, in rat forebrain. Synapse. 2003 Dec 1;50(3):233-9. [PubMed:14515341 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins ...
Gene Name:
HTR2B
Uniprot ID:
P41595
Molecular Weight:
54297.41 Da
References
  1. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW: Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol. 2000 Jan;57(1):75-81. [PubMed:10617681 ]
  2. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL: Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000 Dec 5;102(23):2836-41. [PubMed:11104741 ]
  3. Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL: 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol. 2003 Jun;63(6):1223-9. [PubMed:12761331 ]
  4. Blanpain C, Le Poul E, Parma J, Knoop C, Detheux M, Parmentier M, Vassart G, Abramowicz MJ: Serotonin 5-HT(2B) receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension. Cardiovasc Res. 2003 Dec 1;60(3):518-28. [PubMed:14659797 ]
  5. Kaumann AJ, Levy FO: 5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther. 2006 Sep;111(3):674-706. [PubMed:16960982 ]
  6. Roth BL: Drugs and valvular heart disease. N Engl J Med. 2007 Jan 4;356(1):6-9. [PubMed:17202450 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW: Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol. 2000 Jan;57(1):75-81. [PubMed:10617681 ]
  2. McCreary AC, Filip M, Cunningham KA: Discriminative stimulus properties of (+/-)-fenfluramine: the role of 5-HT2 receptor subtypes. Behav Neurosci. 2003 Apr;117(2):212-21. [PubMed:12708517 ]
  3. Schuhler S, Clark A, Joseph W, Patel A, Lehnen K, Stratford E, Horan TL, Fone KC, Ebling FJ: Involvement of 5-HT receptors in the regulation of food intake in Siberian hamsters. J Neuroendocrinol. 2005 May;17(5):276-85. [PubMed:15869562 ]
  4. Miller KJ: Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity. Mol Interv. 2005 Oct;5(5):282-91. [PubMed:16249524 ]
  5. Nonogaki K, Nozue K, Oka Y: Hyperphagia alters expression of hypothalamic 5-HT2C and 5-HT1B receptor genes and plasma des-acyl ghrelin levels in Ay mice. Endocrinology. 2006 Dec;147(12):5893-900. Epub 2006 Sep 14. [PubMed:16973729 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Haritos VS, Ching MS, Ghabrial H, Gross AS, Taavitsainen P, Pelkonen O, Battaglia SE, Smallwood RA, Ahokas JT: Metabolism of dexfenfluramine in human liver microsomes and by recombinant enzymes: role of CYP2D6 and 1A2. Pharmacogenetics. 1998 Oct;8(5):423-32. [PubMed:9825834 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23